These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1561 related items for PubMed ID: 16900558

  • 21. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
    Cafferata EG, Macció DR, Lopez MV, Viale DL, Carbone C, Mazzolini G, Podhajcer OL.
    Clin Cancer Res; 2009 May 01; 15(9):3037-49. PubMed ID: 19336523
    [Abstract] [Full Text] [Related]

  • 22. A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines.
    Xie M, Niu JH, Chang Y, Qian QJ, Wu HP, Li LF, Zhang Y, Li JL, Huang XJ, Ruan GR.
    Apoptosis; 2009 Sep 01; 14(9):1086-94. PubMed ID: 19551515
    [Abstract] [Full Text] [Related]

  • 23. Midkine promoter-based conditionally replicative adenovirus for targeting midkine-expressing human bladder cancer model.
    Terao S, Shirakawa T, Kubo S, Bishunu A, Lee SJ, Goda K, Tsukuda M, Hamada K, Tagawa M, Takenaka A, Fujisawa M, Gotoh A.
    Urology; 2007 Nov 01; 70(5):1009-13. PubMed ID: 17919690
    [Abstract] [Full Text] [Related]

  • 24. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer.
    Fukuda K, Abei M, Ugai H, Seo E, Wakayama M, Murata T, Todoroki T, Tanaka N, Hamada H, Yokoyama KK.
    Cancer Res; 2003 Aug 01; 63(15):4434-40. PubMed ID: 12907616
    [Abstract] [Full Text] [Related]

  • 25. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo.
    Alonso MM, Cascallo M, Gomez-Manzano C, Jiang H, Bekele BN, Perez-Gimenez A, Lang FF, Piao Y, Alemany R, Fueyo J.
    Cancer Res; 2007 Sep 01; 67(17):8255-63. PubMed ID: 17804740
    [Abstract] [Full Text] [Related]

  • 26. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
    Kuppuswamy M, Spencer JF, Doronin K, Tollefson AE, Wold WS, Toth K.
    Gene Ther; 2005 Nov 01; 12(22):1608-17. PubMed ID: 16034456
    [Abstract] [Full Text] [Related]

  • 27. A bidirectional Tet-dependent promotor construct regulating the expression of E1A for tight control of oncolytic adenovirus replication.
    Fechner H, Wang X, Picó AH, Wildner J, Suckau L, Pinkert S, Sipo I, Weger S, Poller W.
    J Biotechnol; 2007 Jan 20; 127(4):560-74. PubMed ID: 17083991
    [Abstract] [Full Text] [Related]

  • 28. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.
    Bilsland AE, Merron A, Vassaux G, Keith WN.
    Cancer Res; 2007 Feb 01; 67(3):1299-307. PubMed ID: 17283167
    [Abstract] [Full Text] [Related]

  • 29. Telomerase-dependent oncolytic adenovirus for cancer treatment.
    Huang TG, Savontaus MJ, Shinozaki K, Sauter BV, Woo SL.
    Gene Ther; 2003 Aug 01; 10(15):1241-7. PubMed ID: 12858189
    [Abstract] [Full Text] [Related]

  • 30. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
    Wei RC, Cao X, Gui JH, Zhou XM, Zhong D, Yan QL, Huang WD, Qian QJ, Zhao FL, Liu XY.
    Hum Gene Ther; 2011 Sep 01; 22(9):1109-19. PubMed ID: 21361790
    [Abstract] [Full Text] [Related]

  • 31. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
    Bauerschmitz GJ, Guse K, Kanerva A, Menzel A, Herrmann I, Desmond RA, Yamamoto M, Nettelbeck DM, Hakkarainen T, Dall P, Curiel DT, Hemminki A.
    Mol Ther; 2006 Aug 01; 14(2):164-74. PubMed ID: 16580264
    [Abstract] [Full Text] [Related]

  • 32. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth.
    He G, Lei W, Wang S, Xiao R, Guo K, Xia Y, Zhou X, Zhang K, Liu X, Wang Y.
    J Cancer Res Clin Oncol; 2012 Apr 01; 138(4):657-70. PubMed ID: 22237452
    [Abstract] [Full Text] [Related]

  • 33. Targeting KRAS mutation-bearing lung cancer in vivo by pulmonary surfactant-adenovirus-mediated gene transfer.
    Fukazawa T, Maeda Y, Matsuoka J, Ono T, Mominoki K, Yamatsuji T, Shigemitsu K, Morita I, Murakami I, Tanaka H, Durbin ML, Naomoto Y.
    Anticancer Res; 2010 Dec 01; 30(12):4925-35. PubMed ID: 21187472
    [Abstract] [Full Text] [Related]

  • 34. Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus.
    Zhang KJ, Wang YG, Cao X, Zhong SY, Wei RC, Wu YM, Yue XT, Li GC, Liu XY.
    Hum Gene Ther; 2009 Aug 01; 20(8):818-30. PubMed ID: 19320563
    [Abstract] [Full Text] [Related]

  • 35. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model.
    Melquist JJ, Kacka M, Li Y, Malaeb BS, Elmore J, Baseman AG, Hsieh JT, Koeneman KS.
    Urol Oncol; 2006 Aug 01; 24(4):362-71. PubMed ID: 16818192
    [Abstract] [Full Text] [Related]

  • 36. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell.
    Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP, Amin KM.
    Cancer Res; 2002 Jun 15; 62(12):3438-47. PubMed ID: 12067986
    [Abstract] [Full Text] [Related]

  • 37. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
    Zhang Y, Yu D, Xia W, Hung MC.
    Oncogene; 1995 May 18; 10(10):1947-54. PubMed ID: 7761095
    [Abstract] [Full Text] [Related]

  • 38. [The effect of oncolytic adenovirus on human umbilical vein endothelial cell].
    Ye ZM, Wang XH, Zhong J, Miao JC, Sheng WH, Xie YF, Wang JZ, Yang JC.
    Sheng Wu Gong Cheng Xue Bao; 2006 May 18; 22(3):397-402. PubMed ID: 16755917
    [Abstract] [Full Text] [Related]

  • 39. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy.
    Kanai R, Eguchi K, Takahashi M, Goldman S, Okano H, Kawase T, Yazaki T.
    J Gene Med; 2006 Nov 18; 8(11):1329-40. PubMed ID: 16955534
    [Abstract] [Full Text] [Related]

  • 40. Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy.
    McKay TR, Bell S, Tenev T, Stoll V, Lopes R, Lemoine NR, McNeish IA.
    Oncogene; 2003 Jun 05; 22(23):3539-47. PubMed ID: 12789262
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 79.